Comparative overall survival analysis of chordomas of the base of the skull from the Surveillance, Epidemiology, and End Results (SEER) program between 2000 and 2020.


Journal

Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181

Informations de publication

Date de publication:
25 Sep 2024
Historique:
received: 16 05 2024
accepted: 02 09 2024
revised: 31 08 2024
medline: 25 9 2024
pubmed: 25 9 2024
entrez: 25 9 2024
Statut: epublish

Résumé

Chordomas of the skull base are rare, slow growing, locally invasive cancers with limited long-term survival analysis reported in the literature. We seek to provide comparative survival analysis of patients on a long-term (20-year) basis using population-level data. The Surveillance, Epidemiology, and End Results (SEER) program was queried for cases of chordoma relegated to the base of the skull, diagnosed between 2000 and 2020. Demographic, disease, and treatment information were analyzed using Cox proportional hazards and log-rank comparisons. 630 patients with chordoma of the skull base were identified. Age ≤ 49 years at diagnosis was associated with increased five-, 10-, and 20-year overall survival (hazard ratio (HR) = 0.39, 0.33, and 0.30, respectively; p < 0.001 for all). Treatment with surgery and adjuvant radiotherapy was associated with increased five-, 10-, and 20-year survival (HR = 0.71, 0.79, and 0.79, respectively; p < 0.001 for all). On univariate analysis, widowed patients had decreased survival (20-year overall survival = 34.8% [15.3%-34.8%] compared to married patients (74.4% [68.1%-80.8%]. Surgery remains the primary treatment associated with increased survival among patients with chordoma of the skull base, with adjuvant radiotherapy serving a complimentary role. Demographic factors such as marital status are also associated with changes in survival.

Identifiants

pubmed: 39320522
doi: 10.1007/s10143-024-02815-0
pii: 10.1007/s10143-024-02815-0
doi:

Types de publication

Journal Article Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

683

Informations de copyright

© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

Ahmed A-K, Dawood HY, Arnaout OM, Laws ER, Smith TR (2018) Presentation, treatment, and long-term outcome of intrasellar chordoma: a pooled analysis of institutional, SEER (Surveillance Epidemiology and End Results), and published data. World Neurosurg 109:e676–e683. https://doi.org/10.1016/j.wneu.2017.10.054
doi: 10.1016/j.wneu.2017.10.054 pubmed: 29061463
Bohman L-E, Koch M, Bailey RL, Alonso-Basanta M, Lee JYK (2014) Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a seer analysis. World Neurosurg 82:806–814. https://doi.org/10.1016/j.wneu.2014.07.005
doi: 10.1016/j.wneu.2014.07.005 pubmed: 25009165
Chambers KJ, Lin DT, Meier J, Remenschneider A, Herr M, Gray ST (2014) Incidence and survival patterns of cranial chordoma in the United States. Laryngoscope 124:1097–1102. https://doi.org/10.1002/lary.24420
doi: 10.1002/lary.24420 pubmed: 24122844
Di Maio S, Temkin N, Ramanathan D, Sekhar LN (2011) Current comprehensive management of cranial base chordomas: 10-year meta-analysis of observational studies. J Neurosurg 115:1094–1105. https://doi.org/10.3171/2011.7.JNS11355
doi: 10.3171/2011.7.JNS11355 pubmed: 21819197
Hulou MM, Garcia CR, Slone SA, Dugan A, Lei F, Huang B, Pittman T, Villano JL (2019) Comprehensive review of cranial chordomas using national databases in the USA. Clin Oncol 31:e149–e159. https://doi.org/10.1016/j.clon.2019.06.004
doi: 10.1016/j.clon.2019.06.004
Jones PS, Aghi MK, Muzikansky A, Shih HA, Barker FG, Curry WT (2014) Outcomes and patterns of care in adult skull base chordomas from the surveillance, epidemiology, and end results (SEER) database. J Clin Neurosci 21:1490–1496. https://doi.org/10.1016/j.jocn.2014.02.008
doi: 10.1016/j.jocn.2014.02.008 pubmed: 24852903
Lee IJ, Lee RJ, Fahim DK (2017) Prognostic factors and survival outcome in patients with chordoma in the United States: a population-based analysis. World Neurosurg 104:346–355. https://doi.org/10.1016/j.wneu.2017.04.118
doi: 10.1016/j.wneu.2017.04.118 pubmed: 28457925
Li Y, You D, Hu C (2023) Impact of age, race, and gender on the association between marital status and treatment outcomes in oral tongue squamous cell carcinomas. Ear Nose Throat J 1455613231191010. https://doi.org/10.1177/01455613231191010
Li Y, You D, Hu C (2024) Effects of marital status on hypopharynx squamous cell carcinoma survival stratified by demographic and pathological factors: a retrospective study. Ear Nose Throat J 1455613241228079. https://doi.org/10.1177/01455613241228079
Teng C, Yang Q, Xiong Z, Ye N, Li X (2021) Multivariate analysis and validation of the prognostic factors for skull base chordoma. Front Surg 8:764329. https://doi.org/10.3389/fsurg.2021.764329
doi: 10.3389/fsurg.2021.764329 pubmed: 34888345 pmcid: 8649658
Xu J, Shi Q, Wang B, Ji T, Guo W, Ren T, Tang X (2023) The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies. Front Immunol 14:1257254. https://doi.org/10.3389/fimmu.2023.1257254
doi: 10.3389/fimmu.2023.1257254 pubmed: 37720221 pmcid: 10502727
Zhao L, Gong K (2022) Refined efficacy and outcome estimates of surgical treatment in oldest-old patients with glioblastomas based on competing risk model and conditional survival analysis: A surveillance, epidemiology, and end results population-based study. Clin Neurol Neurosurg 221:107391. https://doi.org/10.1016/j.clineuro.2022.107391
doi: 10.1016/j.clineuro.2022.107391 pubmed: 35930955
Zheng W, Huang Y, Guan T, Lu S, Yao L, Wu S, Chen H, Wang N, Liang Y, Xiao W, Jiang X, Wen S (2019) Application of nomograms to predict overall and cancer-specific survival in patients with chordoma. J Bone Oncol 18:100247. https://doi.org/10.1016/j.jbo.2019.100247
doi: 10.1016/j.jbo.2019.100247 pubmed: 31528536 pmcid: 6742804
Zuckerman SL, Bilsky MH, Laufer I (2018) Chordomas of the skull base, mobile spine, and sacrum: an epidemiologic investigation of presentation, treatment, and survival. World Neurosurg 113:e618–e627. https://doi.org/10.1016/j.wneu.2018.02.109
doi: 10.1016/j.wneu.2018.02.109 pubmed: 29486315
Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov ) SEER*Stat Database: Incidence - SEER Research Data, 17 Registries, Nov 2023 Sub (2000–2021) - Linked To County Attributes - Time Dependent (1990–2022) Income/Rurality, 1969–2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission
Ruhl JL, Callaghan C, Schussler N (eds.) (2023) Summary Stage 2018: Codes and Coding Instructions, National Cancer Institute, Bethesda, MD

Auteurs

Kevin E Agner (KE)

The Ohio State University College of Medicine, 370 W. 9Th Avenue, Columbus, OH, 43210, USA.

Michael C Larkins (MC)

East Carolina University Brody School of Medicine, 600 Moye Blvd, Greenville, NC, 27834, USA. larkinsm20@students.ecu.edu.
Department of Emergency Medicine, Boonshoft School of Medicine at Wright State University, 2555 University Blvd, Fairborn, OH, USA. larkinsm20@students.ecu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH